Description of GLP-3
GLP-3 is a synthetic peptide that acts as a triple agonist of the GCG-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and GCG receptors. This combinatorial receptor signaling enables simultaneous modulation of multiple metabolic pathways. In contrast to earlier GLP-1 receptor agonists, which primarily target appetite suppression and glycemic improvement, GLP-3 leverages GCG receptor activation to stimulate lipolysis and elevate basal metabolic rate, thereby contributing to a more pronounced and sustained reduction in adiposity as observed in research models.
The GLP-1 and GIP receptors play essential roles in augmenting insulin secretion and glucose homeostasis, whereas GCG receptor engagement elevates circulating GCG levels, promoting catabolic processes. Through this triagonist mechanism, GLP-3 has been observed in studies to reduce caloric intake and influence glycemic control while also affecting energy expenditure. This comprehensive modulation of energy balance represents a novel research strategy in the investigation of obesity, type 2 diabetes, and related metabolic disorders.
[1]
Overview of Published Research
1. GLP-3 in the Context of Obesity Research
GLP-3 represents a novel generation of research compounds in the anti-obesity and antidiabetic field, characterized by its unique mechanism of action involving the simultaneous activation of three metabolically relevant receptors: the GCG-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the GCG receptor (GCGR). This triple agonism allows for an integrated modulation of key pathways regulating body weight and metabolic homeostasis. GLP-1 and GIP are incretin hormones that have been shown to influence insulin secretion, appetite, and glycemic control, while GCG primarily stimulates lipolysis, increases energy expenditure, and promotes fatty acid oxidation. As a synthetic peptide with an extended half-life, GLP-3 consolidates these effects into a once-weekly injectable formulation studied in clinical trials.
The activity of GLP-3 has been evaluated in several randomized phase 2 clinical trials, demonstrating significant weight reduction. After 48 weeks of treatment, participants receiving 8 mg and 12 mg doses experienced a mean body weight reduction of 22.8% and 24.2%, respectively—an outcome comparable to bariatric surgery. Additional observations included decreases in body mass index (BMI), waist circumference, fasting plasma glucose, HbA1c, and blood pressure. These effects were dose-dependent and particularly pronounced at higher doses. Notably, GLP-3 also exerted a substantial impact on hepatic steatosis, with liver fat volume reduced by up to 82.4% at 12 mg after 24 weeks. A considerable proportion of participants achieved a liver fat content below the threshold for steatosis (<5%), indicating research promise for metabolic liver diseases such as nonalcoholic steatohepatitis (NASH).
Given the high global prevalence of obesity and its strong association with type 2 diabetes and other chronic diseases, GLP-3 emerges as a highly promising research candidate. Ongoing phase 3 trials aim to further establish its long-term safety profile and observed activity. If positive, GLP-3 may be positioned as one of the most significant research innovations in the obesity field in recent decades.
[2] - [5]
2. GLP-3 and Type 2 Diabetes
Recent phase 2 clinical trial data evaluating the activity and safety of GLP-3 in subjects with type 2 diabetes demonstrate its pronounced effects on both glycemic control and body weight reduction. In one of the studies, patients with a mean baseline body mass index (BMI) of 35.3 kg/m² and an average HbA1c of 8.3% were randomized to receive varying doses of GLP-3 (ranging from 1 mg to 12 mg) or placebo over a 36-week study period. GLP-3 exhibited a clear dose-dependent reduction in HbA1c, with the highest dose (12 mg) achieving a mean HbA1c reduction of 2.16 percentage points from baseline, compared to only 0.43% in the placebo group—an effect that was statistically highly significant.
In addition to glycemic changes, a substantial reduction in body weight was also observed. Participants receiving the 12 mg dose of GLP-3 experienced a weight loss of up to 16.94%, corresponding to approximately 17.5 kg, while the placebo group showed a reduction of only 3.29%. The weight loss was consistent throughout the study period and showed a continued downward trend beyond week 36, suggesting a potential for sustained long-term activity. These findings highlight the dual observations with GLP-3 in subjects with type 2 diabetes, combining pronounced glucose-lowering effects with notable anti-obesity properties—particularly relevant given the strong association between obesity, insulin resistance, and impaired glycemic control.
GLP-3, as a triple agonist targeting GLP-1, GIP, and GCG receptors, holds significant promise as a research compound in the investigation of type 2 diabetes—not only through its observed influence on glycemic parameters but also via its substantial impact on weight reduction. Its activity in diabetic study populations approaches outcomes observed in individuals with obesity without diabetes, indicating its potential as a next-generation subject of investigation. These results may inform further research into more individualized approaches in subjects with diabetes and metabolic syndrome, especially in those with significant overweight or obesity.
[6], [7]
3. GLP-3 and Its Liver Impact
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is the most prevalent chronic liver disorder worldwide, with an increasing incidence driven by the global rise in obesity and metabolic syndrome. Pathophysiologically, MASLD is strongly associated with insulin resistance, leading to hepatic lipid accumulation, inflammation, and in advanced stages, fibrosis and cirrhosis.
GLP-3, a novel triple agonist of the GIP, GLP-1, and GCG receptors, has demonstrated significant hepatoprotective effects in research involving individuals with MASLD. In a phase 2 substudy that included participants with hepatic fat content ≥10%, 48-week administration of GLP-3 resulted in a robust, dose-dependent reduction in liver fat. At doses of 8 mg and 12 mg, participants achieved a mean relative reduction in hepatic fat content of 81.4% and 82.4%, respectively, at week 24 (versus +0.3% in the placebo group), with normalization of liver fat content (<5%) observed in 79% and 86% of participants. These effects were sustained at week 48, with 89% and 93% of participants maintaining hepatic fat levels below the steatosis threshold. Additionally, liver volume decreased significantly, and improvements were observed in biomarkers of hepatic injury and inflammation, suggesting potential antifibrotic and anti-inflammatory properties in these models.
The hepatic effects of GLP-3 are likely mediated by multiple mechanisms. Most prominently, the substantial reduction in total and visceral adiposity is tightly linked to improved insulin sensitivity—a core pathophysiological determinant of MASLD. Enhanced insulin action decreases the influx of free fatty acids to the liver and suppresses hepatic de novo lipogenesis. Moreover, administration of GLP-3 resulted in favorable changes in metabolic parameters including glycemia, lipid profile, and inflammatory markers. Given the current lack of approved research compounds for metabolic dysfunction-associated steatohepatitis (MASH)—the progressive form of MASLD characterized by hepatocellular injury and fibrosis—GLP-3 emerges as a highly promising research candidate. Its multifaceted mechanism of action, encompassing weight reduction, metabolic normalization, and marked hepatic fat clearance, underscores its potential role in the further investigation of metabolic liver diseases.
[4]
References
- „Retatrutide (LY3437943): A Novel Tri-agonist Peptide for Metabolic Disease Treatment", 2025.
- Alaa Abdrabou Abouelmagd et al., „Efficacy and safety of retatrutide, a novel GLP-1, GIP, and GCG receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials", 2025.
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple GCG, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234–1247.e9. doi: 10.1016/j.cmet.2022.07.013. [DOI] [PubMed]
- Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037–2048. doi: 10.1038/s41591-024-03018-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–hormone-receptor agonist retatrutide for obesity—a phase 2 trial. N Engl J Med. 2023;389(6):514–526. doi: 10.1056/NEJMoa2301972. [DOI] [PubMed]
- Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and GCG receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529–544. doi: 10.1016/S0140-6736(23)01053-X. [DOI] [PubMed]
- Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and GCG receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869–1881. doi: 10.1016/S0140-6736(22)02033-5. [DOI] [PubMed]
